Sugi Predict

Sugi Predict / Compounds / SCHEMBL2116479

SCHEMBL2116479

SCHEMBL2116479

CS(=O)(=O)OCc1ccc(F)nc1

nearest known ligand 0.38

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ NFE2L2 Q16236 1/20 0.38
▸ CYP11B1 P15538 1/20 0.37
▸ CYP11B2 P19099 1/20 0.37
▸ CA2 P00918 3/20 0.37
▸ CA9 Q16790 2/20 0.37
▸ MMP2 P08253 2/20 0.37
▸ MMP9 P14780 2/20 0.37
▸ MMP8 P22894 2/20 0.37
▸ MMP13 P45452 2/20 0.37
▸ CA1 P00915 2/20 0.36
▸ TLR7 Q9NYK1 1/20 0.35
▸ CNR1 P21554 2/20 0.35
▸ KMT2A Q03164 1/20 0.33
▸ HTR2A P28223 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL394291 0.81 CA2 (0.41) CA2CA9CA1TLR7KMT2A
SCHEMBL30490369 0.81 CA2 (0.41) CA2CA9CA1TLR7KMT2A
SCHEMBL613534 0.79 ALDH1A1 (0.48) KMT2A
SCHEMBL615222 0.79 CYP11B1 (0.37) CYP11B1CA2CA9MMP2MMP9
SCHEMBL22775173 0.79 CA2 (0.42) CA2CA1KMT2AKCNH2
SCHEMBL1608370 0.78 TAS2R14 (0.44) CYP11B1KMT2AKCNH2
SCHEMBL16682861 0.77 CA2 (0.35) CA2CA9CA1TLR7HTR2A
SCHEMBL4952656 0.77 CA2 (0.58) CA2CA9MMP9CA1KMT2A
SCHEMBL344910 0.77 CYP11B1 (0.40) NFE2L2CYP11B1CYP11B2MMP2MMP9
SCHEMBL30328798 0.76 ENPP2 (0.39) CA2CA9CA1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4402139-A1 FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS Bisichem Co., Ltd. (KR) 2024-07-24 — — EP disclosed
US-20240083892-A1 FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS BISICHEM CO., LTD. (KR) 2024-03-14 — — US disclosed
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2024-02-15 — — US disclosed
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-09-14 — — US disclosed
US-11725001-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2023-08-15 — — US disclosed
WO-2023043284-A1 FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS BISICHEM CO., LTD. (KR) 2023-03-23 — — WO disclosed
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF SK BIOPHARMACEUTICALS CO., LTD. 2022-12-22 — — US disclosed
EP-4039686-A1 BICYCLIC COMPOUND AND USE THEREOF SK Biopharmaceuticals Co., Ltd. (KR) 2022-08-10 — — EP disclosed
US-11111237-B2 Bicyclic compound and use thereof SK BIOPHARMACEUTICALS CO., LTD. (KR) 2021-09-07 — — US disclosed
WO-2021066578-A1 BICYCLIC COMPOUND AND USE THEREOF 에스케이바이오팜 주식회사 2021-04-08 — — WO disclosed
US-20130150325-A1 3-(Fluorovinyl)pyrazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-13 — — US disclosed
US-20130150325-A1 3-(Fluorovinyl)pyrazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-13 — — US disclosed
US-20130150325-A1 3-(Fluorovinyl)pyrazoles and their use BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-06-13 — — US disclosed
WO-2013011033-A1 3-(FLUORVINYL)PYRAZOLES AND THE USE THEREOF BAYER INTELLECTUAL PROPERTY GMBH (DE) 2013-01-24 — — WO disclosed
US-8158663-B2 N-[2-thiazolylidene- or 2-oxazolylidene]carbo- or heterocyclecarboxyamides, e.g., 5-chloro-2-methoxy-N-[(2Z)-3-(2-methoxyethyl)-5,5-dimethyl-1,3-thiazolidin-2-ylidene]benzamide; treating neuropathic, nociceptive, and inflammatory pain and immune, respiratory, and cardiovascular disorders ABBOTT LABORATORIES (US) 2012-04-17 — — US disclosed
US-7732456-B2 Pyridone derivative BANYU PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 — — US disclosed
WO-2008079687-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2008-07-03 — — WO disclosed
US-20080153883-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF ABBOTT LABORATORIES (US) 2008-06-26 — — US disclosed
US-20070208046-A1 Pyridone derivative MSD K.K. (JP) 2007-09-06 — — US disclosed
EP-1741703-A1 PYRIDONE DERIVATIVE BANYU PHARMACEUTICAL CO., LTD. (JP) 2007-01-10 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220402902-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 NFE2L2 611/4885CYP11B1 462/4885CYP11B2 430/4885
US-20070208046-A1 Pyridone derivative CHRM1, XDH, MTR NFE2L2 984/4885CYP11B1 477/4885CYP11B2 532/4885
US-20240083892-A1 FUSED HETEROCYCLIC RINGS AS RIPK1 INHIBITORS RIPK1, RIPK3, RIPK4 NFE2L2 4260/4885CYP11B1 2222/4885CYP11B2 3006/4885
US-11111237-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 NFE2L2 611/4885CYP11B1 462/4885CYP11B2 430/4885
US-20130150325-A1 3-(Fluorovinyl)pyrazoles and their use VHL, HIF1AN, HIF1A NFE2L2 120/4885CYP11B1 43/4885CYP11B2 25/4885
US-20240051951-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT1 NFE2L2 611/4885CYP11B1 462/4885CYP11B2 430/4885
US-20230286965-A1 BICYCLIC COMPOUND AND USE THEREOF PRMT5, PRMT6, PRMT8 NFE2L2 852/4885CYP11B1 857/4885CYP11B2 778/4885
US-11725001-B2 Bicyclic compound and use thereof PRMT5, PRMT6, PRMT1 NFE2L2 611/4885CYP11B1 462/4885CYP11B2 430/4885
US-20080153883-A1 NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS AND USES THEREOF CNR1, CNR2, GPR18 NFE2L2 3944/4885CYP11B1 966/4885CYP11B2 1186/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.